A Brief History of Clinical Organ Transplantation

Calne, Sir Roy

doi:10.1002/9781118873434.ch1

Cited by 4 publications

(4 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Transplantation of cells and organs has evolved over the past century from compassionate use experimentation to lifesaving, standard-of-care treatments for a number of diverse conditions, making this one of the great achievements in the history of medicine [1,2]. However, once major breakthroughs in donor tissue preservation and surgical technique were overcome, the prevention and treatment of graft rejection has remained as one of the greatest challenges to patient management and wider application.…”

Section: Introductionmentioning

confidence: 99%

Antibody-Based Preparative Regimens for Cell, Tissue and Organ Transplantation

Hentenryck,

Li,

Murphy

et al. 2021

OBM Transplant

View full text Add to dashboard Cite

The ability to successfully transplant cells and organs from a donor into an immunologically disparate recipient is one of the greatest treatment advances in the history of medicine. Nevertheless, acute and chronic rejection, graft versus host disease, and the inability to identify suitable donors continue to be challenges and limit broader application of cell and organ transplantation to the many patients that could benefit. Immunosuppression before and after allogeneic transplant has been found to dramatically improve allograft survival and, despite side effects, has been a mainstay of patient management. Inducing donor-specific tolerance is the holy grail in allotransplantation and is readily established in experimental animals but has been difficult to achieve in patients in settings apart from hematopoietic cell transplantation. Antibody-based conditioning to prepare the recipient is a promising approach towards achieving transplant tolerance in both hematopoietic and solid organ transplant settings, and multiple targets are currently under consideration including those on circulating lymphocytes and hematopoietic stem cells. Here we review progress in the use of antibodies to support cell and tissue transplantation with a particular focus on induction of donor-specific tolerance for solid organ transplantation.

show abstract

Section: Introductionmentioning

confidence: 99%

Antibody-Based Preparative Regimens for Cell, Tissue and Organ Transplantation

Hentenryck,

Li,

Murphy

et al. 2021

OBM Transplant

View full text Add to dashboard Cite

show abstract

“…LT has been performed since the 1960s, although the early attempts had limited success. 1,2 Since that time, LT has continued to evolve in terms of application and long-term success and is now a viable treatment. 3 It has been suggested that complications in the early post-operative survival period seeds the development of progressive pulmonary disorders.…”

mentioning

confidence: 99%

The potential role of microRNAs in lung allograft rejection

Ladak

Ward

Ali

2016

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Lung transplantation (LT) has proven to be successful in carefully selected individuals with end-stage lung disease. However, long-term graft survival post-LT is often hindered by the development of the bronchiolitis obliterans syndrome (BOS). Because BOS represents is a major problem for all LT centers, early identification and prediction of progressive loss of lung function is a major goal. MicroRNAs (miRNAs) play a major role in regulating many cellular functions, including epithelial-to-mesenchymal transition. miRNAs are emerging not only as biomarkers but also as potential therapy. The recognized importance of injured human bronchial epithelium in lung allograft dysfunction indicates that there is a need for research into the potential role of miRNAs. In this we review we summarize published findings in miRNAs implicated in lung and other types of allograft dysfunction and their role in maintaining the phenotype of epithelial cells after transplant injury. We also address potential clinical interventions that involve manipulating miRNA expression that may promote long-term airway integrity and graft survival.

show abstract

“…Since the first living donor kidney transplant in 1954, the efficacy of transplantation has improved due to advances in immunosuppressive therapy and a more comprehensive understanding of the immune response [2]. The utilization of corticosteroids and the introduction of azathioprine in the 1960s and 1970s were important breakthroughs.…”

mentioning

confidence: 99%